Tag:
Firazyr
Latest Headlines
Latest Headlines
New drug nods for J&J, Lilly/BI, and Shire
Between FDA and European regulators, we've had three new drug approvals in 24 hours. That should give drug-launch aficionados plenty to contemplate over the weekend, even if they're trapped inside by
Shire battles back to win FDA OK for HAE drug Firazyr
Three years after dismissing an application for Firazyr (icatibant) after citing the company for insufficient trial data, regulators at the FDA this morning stamped Shire's ( $SHPGY ) new drug for
Panel backs Shire's hereditary angioedema drug
In a 12 to one vote, an FDA panel backed Shire's Firazyr (icatibant) for acute attacks of hereditary angioedema (HAE) in patients 18 years and older. The panel also said patients should be able to
